RU2015143490A - Способы лечения рака мочевого пузыря - Google Patents

Способы лечения рака мочевого пузыря Download PDF

Info

Publication number: RU2015143490A
Authority: RU; Russia
Prior art keywords: nanoparticles; therapeutic agent; bladder cancer; composition; individual
Prior art date: 2013-03-14

Application number

RU2015143490A

Other languages

English (en)

Russian (ru)

Other versions

RU2015143490A3 (2

Inventor

Нейл П. ДИСЭЙ

Original Assignee

АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-14

Filing date

2014-03-13

Publication date

2017-04-26

2014-03-13 Application filed by АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи filed Critical АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи

2017-04-26 Publication of RU2015143490A publication Critical patent/RU2015143490A/ru

2018-03-13 Publication of RU2015143490A3 publication Critical patent/RU2015143490A3/ru

Links

238000000034 method Methods 0.000 title claims 59
206010005003 Bladder cancer Diseases 0.000 title claims 14
208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims 12
201000005112 urinary bladder cancer Diseases 0.000 title claims 12
239000003814 drug Substances 0.000 claims 25
239000002105 nanoparticle Substances 0.000 claims 17
229940124597 therapeutic agent Drugs 0.000 claims 14
229940079593 drug Drugs 0.000 claims 11
102000006311 Cyclin D1 Human genes 0.000 claims 8
108010058546 Cyclin D1 Proteins 0.000 claims 8
102100038895 Myc proto-oncogene protein Human genes 0.000 claims 8
101710135898 Myc proto-oncogene protein Proteins 0.000 claims 8
101710150448 Transcriptional regulator Myc Proteins 0.000 claims 8
102000018252 Tumor Protein p73 Human genes 0.000 claims 8
108010091356 Tumor Protein p73 Proteins 0.000 claims 8
102000009027 Albumins Human genes 0.000 claims 5
108010088751 Albumins Proteins 0.000 claims 5
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 5
239000000090 biomarker Substances 0.000 claims 4
239000002955 immunomodulating agent Substances 0.000 claims 4
229960004857 mitomycin Drugs 0.000 claims 3
235000005979 Citrus limon Nutrition 0.000 claims 2
244000131522 Citrus pyriformis Species 0.000 claims 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
102000014150 Interferons Human genes 0.000 claims 2
108010050904 Interferons Proteins 0.000 claims 2
229940079322 interferon Drugs 0.000 claims 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
229960002930 sirolimus Drugs 0.000 claims 2
206010044412 transitional cell carcinoma Diseases 0.000 claims 2
208000023747 urothelial carcinoma Diseases 0.000 claims 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
229930192392 Mitomycin Natural products 0.000 claims 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
229930012538 Paclitaxel Natural products 0.000 claims 1
229940123237 Taxane Drugs 0.000 claims 1
229940100198 alkylating agent Drugs 0.000 claims 1
239000002168 alkylating agent Substances 0.000 claims 1
239000003817 anthracycline antibiotic agent Substances 0.000 claims 1
230000000340 anti-metabolite Effects 0.000 claims 1
229940100197 antimetabolite Drugs 0.000 claims 1
239000002256 antimetabolite Substances 0.000 claims 1
-1 apaziquon Chemical compound 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
229960004316 cisplatin Drugs 0.000 claims 1
229960003668 docetaxel Drugs 0.000 claims 1
229960004679 doxorubicin Drugs 0.000 claims 1
229960001904 epirubicin Drugs 0.000 claims 1
229960005277 gemcitabine Drugs 0.000 claims 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims 1
210000003205 muscle Anatomy 0.000 claims 1
229960001592 paclitaxel Drugs 0.000 claims 1
229910052697 platinum Inorganic materials 0.000 claims 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
229960000653 valrubicin Drugs 0.000 claims 1
ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Nanotechnology (AREA)
Gynecology & Obstetrics (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)

RU2015143490A 2013-03-14 2014-03-13 Способы лечения рака мочевого пузыря RU2015143490A (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201361786175P	2013-03-14	2013-03-14
US201361786167P	2013-03-14	2013-03-14
US61/786,167		2013-03-14
US61/786,175		2013-03-14
PCT/US2014/026564 WO2014151853A1 (en)	2013-03-14	2014-03-13	Methods of treating bladder cancer

Publications (2)

Publication Number	Publication Date
RU2015143490A true RU2015143490A (ru)	2017-04-26
RU2015143490A3 RU2015143490A3 (2)	2018-03-13

Family

ID=51581053

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2015143490A RU2015143490A (ru)	2013-03-14	2014-03-13	Способы лечения рака мочевого пузыря

Country Status (17)

Country	Link
US (3)	US9962373B2 (2)
EP (1)	EP2968191B1 (2)
JP (3)	JP6309610B2 (2)
KR (1)	KR20150127187A (2)
CN (2)	CN110934852A (2)
AU (2)	AU2014236802B2 (2)
BR (1)	BR112015022047A8 (2)
CA (1)	CA2903548A1 (2)
ES (1)	ES2881851T3 (2)
HK (1)	HK1220405A1 (2)
IL (2)	IL240983B (2)
MX (1)	MX378934B (2)
NZ (1)	NZ630213A (2)
RU (1)	RU2015143490A (2)
SG (1)	SG11201507234UA (2)
WO (1)	WO2014151853A1 (2)
ZA (1)	ZA201506877B (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
EP3470071A1 (en)	2006-12-14	2019-04-17	Abraxis BioScience, LLC	Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
EP2131821B1 (en) *	2007-03-07	2018-05-09	Abraxis BioScience, LLC	Nanoparticle comprising rapamycin and albumin as anticancer agent
PT2419732T (pt)	2009-04-15	2019-12-24	Abraxis Bioscience Llc	Composições e métodos de nanopartículas isentas de priões
EP3141245A1 (en)	2010-03-29	2017-03-15	Abraxis BioScience, LLC	Methods of treating cancer
MX2012011155A (es)	2010-03-29	2012-12-05	Abraxis Bioscience Llc	Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es)	2010-06-04	2017-04-19	Abraxis Bioscience Llc *	Metodos de tratamiento contra el cancer pancreatico.
KR101970342B1 (ko)	2011-04-28	2019-04-18	아브락시스 바이오사이언스, 엘엘씨	나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en)	2011-12-14	2019-10-30	Abraxis BioScience, LLC	Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en)	2012-11-09	2015-10-06	Abraxis Bioscience, Llc	Methods of treating melanoma
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
EP3698784A1 (en)	2013-03-12	2020-08-26	Abraxis BioScience, LLC	Methods of treating lung cancer
RU2015143490A (ru)	2013-03-14	2017-04-26	АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи	Способы лечения рака мочевого пузыря
ES2881214T3 (es) *	2014-12-17	2021-11-29	Pfizer	Formulaciones de un inhibidor de PI3K/mTOR para la administración intravenosa
WO2016105503A1 (en) *	2014-12-24	2016-06-30	Genentech, Inc.	Therapeutic, diagnostic and prognostic methods for cancer of the bladder
US10527604B1 (en)	2015-03-05	2020-01-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en)	2015-03-05	2020-07-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
WO2016169042A1 (en) *	2015-04-24	2016-10-27	Genedia Biotech Co. Ltd.	Combination therapies for bladder cancer
KR20240144442A (ko) *	2015-06-29	2024-10-02	아브락시스 바이오사이언스, 엘엘씨	나노입자 조성물에 대한 바이오마커
JP2018521058A (ja) *	2015-06-29	2018-08-02	アブラクシスバイオサイエンス，エルエルシー	ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
ES3009356T3 (en)	2015-06-29	2025-03-26	Abraxis Bioscience Llc	Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
CN107921050A (zh) *	2015-06-29	2018-04-17	阿布拉科斯生物科学有限公司	使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
EP3518923A4 (en) *	2016-09-28	2020-06-17	Abraxis BioScience, LLC	METHOD FOR TREATING MITOCHONDRIAL AND METABOLIC DISORDERS
IL277402B1 (en)	2018-03-20	2026-04-01	Abraxis Bioscience Llc	Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
EP3924521A4 (en)	2019-02-15	2023-03-29	IncellDx, Inc.	BLADDER-ASSOCIATED SAMPLES TESTING, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREON
KR102936433B1 (ko) *	2019-03-19	2026-03-09	아브락시스 바이오사이언스, 엘엘씨	질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여
BR112022007710A2 (pt)	2019-10-28	2022-07-12	Abraxis Bioscience Llc	Composições farmacêuticas de albumina e rapamicina
TW202123935A (zh) *	2019-11-11	2021-07-01	美商亞伯辛生物科學有限責任公司	用於奈米粒子組合物之生物標記
EP4167958A1 (en) *	2020-06-19	2023-04-26	Yale University	Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance
US20230178177A1 (en) *	2020-06-30	2023-06-08	Northwestern University	A single patient classifier for t1 high grade bladder cancer
WO2024081674A1 (en)	2022-10-11	2024-04-18	Aadi Bioscience, Inc.	Combination therapies for the treatment of cancer

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5997904A (en)	1993-02-22	1999-12-07	American Bioscience, Inc.	Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en)	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US6749868B1 (en)	1993-02-22	2004-06-15	American Bioscience, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030068362A1 (en)	1993-02-22	2003-04-10	American Bioscience, Inc.	Methods and formulations for the delivery of pharmacologically active agents
US5650156A (en)	1993-02-22	1997-07-22	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en)	1993-03-26	1994-11-08	Vivorx Pharmaceuticals, Inc.	Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665382A (en)	1993-02-22	1997-09-09	Vivorx Pharmaceuticals, Inc.	Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en)	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
NZ262679A (en)	1993-02-22	1997-08-22	Vivorx Pharmaceuticals Inc	Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US6096331A (en)	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US5665383A (en)	1993-02-22	1997-09-09	Vivorx Pharmaceuticals, Inc.	Methods for the preparation of immunostimulating agents for in vivo delivery
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US6528067B1 (en)	1993-02-22	2003-03-04	American Bioscience, Inc.	Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6565842B1 (en)	1995-06-07	2003-05-20	American Bioscience, Inc.	Crosslinkable polypeptide compositions
US8137684B2 (en)	1996-10-01	2012-03-20	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en)	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
PT1023050E (pt)	1997-06-27	2013-12-04	Abraxis Bioscience Llc	Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1171117A4 (en)	1999-04-22	2002-08-07	American Bioscience Inc	LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
HK1045646A1 (zh)	1999-05-21	2002-12-06	Abraxis Bioscience, Llc	蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
ITMI20001107A1 (it)	2000-05-18	2001-11-18	Acs Dobfar Spa	Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020680A1 (it)	2002-03-29	2003-09-29	Acs Dobfar Spa	Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it)	2002-03-29	2003-09-29	Acs Dobfar Spa	Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
CA2509365C (en)	2002-12-09	2012-08-07	American Bioscience, Inc.	Compositions and methods of delivery of pharmacological agents
KR20120068035A (ko)	2002-12-09	2012-06-26	아브락시스 바이오사이언스, 엘엘씨	약리학적 물질의 조성물 및 그 전달방법
US20070166388A1 (en)	2005-02-18	2007-07-19	Desai Neil P	Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko)	2005-02-18	2007-12-04	아브락시스 바이오사이언스 인크.	치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
LT3311805T (lt)	2005-08-31	2020-04-27	Abraxis Bioscience, Llc	Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3527202A1 (en)	2005-08-31	2019-08-21	Abraxis BioScience, LLC	Compositions and methods for preparation of poorly water soluble drugs with increased stability
US8585753B2 (en) *	2006-03-04	2013-11-19	John James Scanlon	Fibrillated biodegradable prosthesis
EP2056812A1 (en)	2006-08-31	2009-05-13	Abraxis BioScience, LLC	Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20080280987A1 (en)	2006-08-31	2008-11-13	Desai Neil P	Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP2121018A2 (en) *	2006-12-13	2009-11-25	Schering Corporation	Treating cancer with anti-igf1r antibody 19d12=sch 717454
EP3470071A1 (en)	2006-12-14	2019-04-17	Abraxis BioScience, LLC	Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
CN101730526A (zh) *	2007-03-07	2010-06-09	阿布拉科斯生物科学有限公司	作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
EP2131821B1 (en)	2007-03-07	2018-05-09	Abraxis BioScience, LLC	Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2013204187B2 (en) *	2007-03-07	2015-10-01	Abraxis Bioscience, Llc	Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en)	2007-05-03	2010-07-01	Desai Neil P	Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja)	2007-06-01	2014-08-27	アブラクシスバイオサイエンス，エルエルシー	再発性癌の処置のための方法および組成物
US20110014117A1 (en) *	2007-06-28	2011-01-20	Schering Corporation	Anti-igf1r
TW200942233A (en)	2008-04-10	2009-10-16	Abraxis Bioscience Llc	Compositions of hydrophobic taxane derivatives and uses thereof
MX2010011165A (es)	2008-04-10	2011-02-22	Abraxis Bioscience Llc	Composiciones de derivados de taxano hidrofobos y sus usos.
US20110129456A1 (en) *	2008-05-05	2011-06-02	Yaolin Wang	Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
CA2746129A1 (en)	2008-12-11	2010-06-17	Abraxis Bioscience, Llc	Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals
WO2010105172A1 (en)	2009-03-13	2010-09-16	Abraxis Bioscience, Llc	Combination therapy with thiocolchicine derivatives
CA2758200A1 (en)	2009-04-10	2010-10-14	Abraxis Bioscience, Llc	Nanoparticle formulations and uses thereof
PT2419732T (pt)	2009-04-15	2019-12-24	Abraxis Bioscience Llc	Composições e métodos de nanopartículas isentas de priões
EP3103452A1 (en) *	2009-08-25	2016-12-14	Abraxis BioScience, LLC	Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
EP2502078A1 (en)	2009-11-20	2012-09-26	Infinity Pharmaceuticals, Inc.	Methods and compositions for treating hedgehog-associated cancers
NZ602382A (en)	2010-03-26	2014-11-28	Abraxis Bioscience Llc	Methods of treatment of hepatocellular carcinoma
MX2012011155A (es)	2010-03-29	2012-12-05	Abraxis Bioscience Llc	Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (en)	2010-03-29	2017-03-15	Abraxis BioScience, LLC	Methods of treating cancer
CA2801314A1 (en) *	2010-06-02	2011-12-08	Abraxis Bioscience, Llc	Methods of treating bladder cancer
MX347225B (es)	2010-06-04	2017-04-19	Abraxis Bioscience Llc *	Metodos de tratamiento contra el cancer pancreatico.
JP6031437B2 (ja)	2010-06-07	2016-11-24	アブラクシスバイオサイエンス，エルエルシー	増殖性疾患を処置するための組み合わせ療法
US9636309B2 (en) *	2010-09-09	2017-05-02	Micell Technologies, Inc.	Macrolide dosage forms
KR101970342B1 (ko)	2011-04-28	2019-04-18	아브락시스 바이오사이언스, 엘엘씨	나노입자 조성물의 혈관내 전달 및 그의 용도
AU2012249474A1 (en) *	2011-04-28	2013-11-07	Stc.Unm	Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
EP3560486A1 (en)	2011-12-14	2019-10-30	Abraxis BioScience, LLC	Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en)	2012-11-09	2015-10-06	Abraxis Bioscience, Llc	Methods of treating melanoma
US20140186447A1 (en)	2012-12-28	2014-07-03	Abraxis Bioscience, Llc	Nanoparticle compositions of albumin and paclitaxel
US20140199404A1 (en)	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on level of a nucleoside transporter
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
US20140199405A1 (en)	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on mutation status of k-ras
KR102148551B1 (ko)	2013-02-11	2020-08-26	아브락시스 바이오사이언스, 엘엘씨	흑색종을 치료하는 방법
EP3698784A1 (en)	2013-03-12	2020-08-26	Abraxis BioScience, LLC	Methods of treating lung cancer
JP6387389B2 (ja)	2013-03-13	2018-09-05	アブラクシスバイオサイエンス，エルエルシー	小児充実性腫瘍の処置の方法
RU2015143490A (ru)	2013-03-14	2017-04-26	АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи	Способы лечения рака мочевого пузыря
WO2015157120A1 (en)	2014-04-06	2015-10-15	Abraxis Bioscience, Llc	Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
WO2016141365A1 (en)	2015-03-05	2016-09-09	Abraxis Bioscience, Llc	Method for treating cancer based on level of glucocorticoid receptor
CN107921050A (zh)	2015-06-29	2018-04-17	阿布拉科斯生物科学有限公司	使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
JP2018521058A (ja)	2015-06-29	2018-08-02	アブラクシスバイオサイエンス，エルエルシー	ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
KR20240144442A (ko)	2015-06-29	2024-10-02	아브락시스 바이오사이언스, 엘엘씨	나노입자 조성물에 대한 바이오마커
ES3009356T3 (en)	2015-06-29	2025-03-26	Abraxis Bioscience Llc	Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
US20170181988A1 (en)	2015-12-23	2017-06-29	Cipla Limited	Methods for the treatment of bladder cancer
US20180374583A1 (en)	2017-05-16	2018-12-27	Abraxis Bioscience, Llc	Nomogram and survival predictions for pancreatic cancer

2014
- 2014-03-13 RU RU2015143490A patent/RU2015143490A/ru unknown
- 2014-03-13 HK HK16108595.4A patent/HK1220405A1/zh unknown
- 2014-03-13 WO PCT/US2014/026564 patent/WO2014151853A1/en not_active Ceased
- 2014-03-13 MX MX2015011753A patent/MX378934B/es unknown
- 2014-03-13 EP EP14767736.3A patent/EP2968191B1/en active Active
- 2014-03-13 JP JP2016502177A patent/JP6309610B2/ja active Active
- 2014-03-13 KR KR1020157027995A patent/KR20150127187A/ko not_active Ceased
- 2014-03-13 US US14/772,725 patent/US9962373B2/en active Active
- 2014-03-13 CA CA2903548A patent/CA2903548A1/en not_active Abandoned
- 2014-03-13 CN CN201911310288.1A patent/CN110934852A/zh active Pending
- 2014-03-13 ES ES14767736T patent/ES2881851T3/es active Active
- 2014-03-13 SG SG11201507234UA patent/SG11201507234UA/en unknown
- 2014-03-13 BR BR112015022047A patent/BR112015022047A8/pt not_active Application Discontinuation
- 2014-03-13 NZ NZ630213A patent/NZ630213A/en unknown
- 2014-03-13 CN CN201480027976.6A patent/CN105246468A/zh active Pending
- 2014-03-13 AU AU2014236802A patent/AU2014236802B2/en active Active
2015
- 2015-09-01 IL IL240983A patent/IL240983B/en active IP Right Grant
- 2015-09-16 ZA ZA2015/06877A patent/ZA201506877B/en unknown
2018
- 2018-01-25 JP JP2018010608A patent/JP2018062531A/ja active Pending
- 2018-03-28 US US15/938,952 patent/US10413531B2/en active Active
2019
- 2019-03-11 AU AU2019201640A patent/AU2019201640A1/en not_active Abandoned
- 2019-08-16 US US16/543,196 patent/US20200138793A1/en not_active Abandoned
2020
- 2020-01-08 JP JP2020001289A patent/JP2020050680A/ja active Pending
- 2020-04-06 IL IL273856A patent/IL273856A/en unknown

Also Published As

Publication number	Publication date
SG11201507234UA (en)	2015-10-29
US20200138793A1 (en)	2020-05-07
JP2020050680A (ja)	2020-04-02
JP2016513657A (ja)	2016-05-16
HK1220405A1 (zh)	2017-05-05
US9962373B2 (en)	2018-05-08
ZA201506877B (en)	2017-11-29
US20180214425A1 (en)	2018-08-02
KR20150127187A (ko)	2015-11-16
ES2881851T3 (es)	2021-11-30
IL273856A (en)	2020-05-31
AU2014236802A1 (en)	2015-09-24
EP2968191A1 (en)	2016-01-20
AU2019201640A1 (en)	2019-04-04
MX378934B (es)	2025-03-11
AU2014236802B2 (en)	2019-01-03
CN110934852A (zh)	2020-03-31
US10413531B2 (en)	2019-09-17
US20160008330A1 (en)	2016-01-14
CA2903548A1 (en)	2014-09-25
MX2015011753A (es)	2015-12-07
CN105246468A (zh)	2016-01-13
JP2018062531A (ja)	2018-04-19
JP6309610B2 (ja)	2018-04-11
NZ630213A (en)	2017-05-26
WO2014151853A1 (en)	2014-09-25
BR112015022047A2 (pt)	2017-07-18
EP2968191B1 (en)	2021-06-16
EP2968191A4 (en)	2016-11-16
RU2015143490A3 (2)	2018-03-13
IL240983A0 (en)	2015-11-30
IL240983B (en)	2020-04-30
BR112015022047A8 (pt)	2019-12-10

Publication	Publication Date	Title
RU2015143490A (ru)	2017-04-26	Способы лечения рака мочевого пузыря
JP2016513657A5 (2)	2017-04-06
Liu et al.	2014	pH-sensitive nano-systems for drug delivery in cancer therapy
JP2013527232A5 (2)	2014-07-03
RU2012157805A (ru)	2014-07-20	Способы лечения рака мочевого пузыря
JP2015512953A5 (2)	2016-06-09
RU2016112608A (ru)	2017-11-16	Лечение рака комбинацией плинабулина и таксана
RU2007134571A (ru)	2009-03-27	Комбинация и способы введения терапевтических средств и комбинированной терапии
ME02470B (me)	2017-02-20	Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
CN103099782B (zh)	2014-07-16	核-壳型纳米药物颗粒、其制备方法及应用
JP2019521180A5 (2)	2020-07-16
JP2013503174A5 (2)	2013-10-10
JP2010512384A5 (2)	2011-02-10
JP2010523696A5 (2)	2011-07-14
JP2017516802A5 (2)	2018-08-30
Zhou et al.	2016	Preparation, characterization, and antitumor evaluation of electrospun resveratrol loaded nanofibers
JP2018536655A5 (2)	2019-12-05
Kobayashi et al.	2007	Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
Ueda et al.	2010	Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
WO2017200492A1 (en)	2017-11-23	Method of treating cancer
CN109419773B (zh)	2022-06-17	复合纳米脂质给药系统及其对妇科肿瘤的治疗作用
Kekez et al.	2014	Fluorouracil, leucovorin and irinotecan combined with intra-arterial hepatic infusion of drug-eluting beads preloaded with irinotecan in unresectable colorectal liver metastases: side effects and results of a concomitant treatment schedule. Clinical investigation
EP4157457A1 (en)	2023-04-05	Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof
TWI719182B (zh)	2021-02-21	奈米組成物、其製造方法及其用途
Jafari et al.	2019	Targeted drug delivery of capecitabine to mice xenograft gastric cancer by PAMAM dendrimer nanocarrier